Towards Healthcare
Oncology Biosimilars Market Reach at 18.47% CAGR till 2034

Oncology Biosimilars Market 2025 Insights - Dominated by Breast Cancer Segment, Monoclonal Antibodies to Lead Future Growth

Market insights predict, the oncology biosimilars industry is expected to grow from USD 6.7 billion in 2024 to USD 36.23 billion by 2034, driven by a CAGR of 18.47%. The oncology biosimilars market is witnessing rapid growth, offering similar and clinically equivalent alternatives to biologic cancer treatments. North America is leading the market as the government is focused on reducing financial burden due to healthcare because biosimilars are developed to provide the same outcomes at a reduced cost, balancing clinical access with less financial burden.

  • Insight Code: 6020
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The oncology biosimilars market in 2025 is valued at USD 7.94 billion and is projected to climb to USD 36.23 billion by 2034, with a CAGR of 18.47% over the forecast period.

North America is currently leading the oncology biosimilars market due to a drive in advanced oncology infrastructure, development in healthcare practices, advanced technological integrations, and scientific advancements.

The oncology biosimilars market includes six segments such as by indication, by drug class, by route of administration, by end-user, by distribution channel, and by region.

Some key players include Samsung Bioepis Co., Celltrion, Amgen Inc., Mylan N.V., Allergan, and Novartis International AG.

The Biologics Price Competition Innovation Act (BPCIA) helps to streamline approvals and encourage competition

FDA, WHO, UNICEF, PIB, National Institutes of Health.